There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.
Lytle ME, Vander Bilt J, Pandav RS, Dodge HH, Ganguli M. Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord. 2004;18:57-64.
2.
Gatz M.Educating the brain to avoid dementia: can mental exercise prevent Alzheimer disease?PLoS Med.2005;2:e7.
3.
Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RSVitamin E and cognitive decline in older persons. Arch Neurol.2002;59:1125-1132.
4.
Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol.2004;61:82-88.
5.
Commenges D. , Scotet V., Renaud S., Jacqmin-Gadda H., Barberger-Gateau P., Dartiques JFIntake of flavonoids and risk of dementia. Eur J Epidemiol.2000 ;16:357-363.
6.
Engelhart MJ , Geerlings MI, Ruitenberg A., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA.2002;287:3223-3229.
7.
Kalmijn S., Feskens EJ, Launer LJ, Kromhout D.Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol.1997;145:33-41.
8.
Clarke R., Smith AD, Jobst KA, Refsum H., Sutton L., Ueland PMFolate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol.1998;55:1449-1455.
9.
Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JLA potential role of the curry spice cur-cumin in Alzheimer's disease . Curr Alzheimer Res.2005;2:131-136.
10.
Luchsinger JA, Tang MX, Shea S., Mayeux R.Caloric intake and the risk of Alzheimer disease . Arch Neurol.2002;59:1258-1263.
11.
Scarmeas N. , Stern Y., Tang MX, Mayeux R., Luchsinger JAMediterranean diet and risk for Alzheimer's disease. Ann Neurol.2006;59:912-921.
12.
Ruitenberg A., van Swieten JC, Witteman JC, et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet. 2002;359:281-286.
13.
Sparks DL, Sabbagh M., Connor D., et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl.2006;185:78-86.
14.
Birkenhager WH, Staessen JAAntihypertensives for prevention of Alzheimer's disease. Lancet Neurol.2006 ;5:466-468.
15.
Sun MK, Alkon DLLinks between Alzheimer's disease and diabetes. Drugs Today (Barc).2006;42:481-489.
16.
McGeer PL, McGeer EGAnti-inflammatory drugs in the fight against Alzheimer's disease. Ann NY Acad Sci.1996 ;777:213-220.
17.
Shumaker SA , Legault C., Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA.2003;289:2651-2662.
18.
Shumaker SA , Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA.2004; 291:2947-2958.
19.
Rogers SL, Farlow MR, Doody RS, Mohs R., Friedhoff LTA 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology . 1998;50:136-145.
20.
Rösler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ.1999;318:633-638.
21.
Raskind MA, Peskind ER, Wessel T., Yuan W.Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology.2000;54:2261-2268.
22.
Reisberg B. , Doody R., Stöffler A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med.2003;348:1333-1341.
23.
Moretti R., Torre P., Antonello RM, Cattaruzza T., Cazzato G., Bava A.Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931-937.
24.
Freedman M.Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. Can J Neurol Sci.2007;34(suppl 1):S118-S124.
25.
Mendez MF, Shapira JS, McMurtray A., Licht E.Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84-87.
26.
Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
27.
Birks J.Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev.2006;CD005593.
28.
Lleo A., Greenberg SM, Growdon JHCurrent pharmacotherapy for Alzheimer's disease. Annu Rev Med.2006; 57:513-533.
29.
Rogers SL, Doody RS, Pratt RD, Ieni JRLong-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol.2000;10: 195-203.
30.
Raskind MA, Peskind ER, Truyen L., Kershaw P., Damaraju CVThe cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol.2004;61:252-256.
31.
Feldman H., Gauthier S., Hecker J., et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004;63:644-650.
32.
Wynn ZJ, Cummings JLCholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dementia Geriatr Cogn Disord. 2004;17:100-108.
33.
Tune LEDepression and Alzheimer's disease. Depress Anxiety.1998;8(suppl 1):91-95.
34.
Schenck CH, Mahowald MW, Kim SW, O'Connor KA, Hurwitz TDProminent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep.1992;15:226-235.
35.
Herrmann N. , Rabheru K., Wang J., Binder C.Galantamin treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials . Am J Geriatr Psychiatry. 2005;13:527-534.
36.
Salzman C.Treatment of the agitation of late-life psychosis and Alzheimer's disease . Eur Psychiatry.2001;16 (suppl 1):25s-28s.
37.
Devanand DPBehavioral complications and their treatment in Alzheimer's disease. Geriatrics.1997;52(suppl 2):S37-S39.
38.
Sink KM, Holden KF, Yaffe K.Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA.2005;293:596-608.
39.
Schneider LS , Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med.2006;355: 1525-1538.
40.
Kurlan R., Cummings J., Raman R., Thal L. for the ADCS.Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology . 2007;68: 1356-1363.
41.
Wang PS, Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med.2005 ;353:2335-2341.
42.
Liu W., Miller BL, Kramer JH, et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology. 2004;62:742-748.
43.
Devanand DPBehavioral complications and their treatment in Alzheimer's disease. Geriatrics.1997;52(suppl 2):S37-S39.
44.
Shelton PS, Hocking LBZolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother.1997;31:319-322.
45.
Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JEAssociation of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord.2001;16:622-630.
46.
Kadotani H. , Kadotani T., Young T., et al. Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults . JAMA.2001;285:2888-2890.
47.
Gottlieb DJ , DeStefano AL, Foley DJ, et al. APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. Neurology . 2004;63: 664-668.
48.
Hodges JR, Davies R., Xuereb J., Kril J., Halliday G.Survival in frontotemporal dementia. Neurology. 2003;61:349-354.
49.
Kalisvaart KJ, de Jonghe JF, Bogaards MJ, et al. Haloperidol prophylaxis for elderly hip surgery patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc.2005;53:1658-1666.
50.
Morris JCThe Clinical Dementia Rating (CDR): current version and scoring rules . Neurology. 1993;43:2412-2414.
51.
Petersen RC , Stevens JC, Ganguli M., Tangalos EG, Cummings JL, DeKosky STPractice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.2001;56:1133-1142.
52.
Petersen RC , Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol.2001;58:1985-1992.
53.
Winblad B., Palmer K., Kivipelto M., et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment . J Intern Med.2004;256:240-246.
54.
Dubinsky RM , Stein AC, Lyons K.Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology . Neurology.2000;54:2205-2211.
55.
Caselli RJVisual syndromes as the presenting feature of degenerative brain disease . Semin Neurol.2000;20:139-144.
56.
Drachman DA , Swearer JMDriving and Alzheimer's disease: the risk of crashes. Neurology. 1993;43: 2448-2456.
57.
Logsdon RG, Teri L., Larson EBDriving and Alzheimer's disease. J Gen Intern Med.1992;7:583-588.
58.
Fitten LJ, Perryman KM, Wilkinson CJ, et al. Alzheimer and vascular dementias and driving. A prospective road and laboratory study. JAMA.1995;273:1360-1365.
59.
Hunt LA, Murphy CF, Carr D., Duchek JM, Buckles V., Morris JCReliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Arch Neurol.1997;54:707-712.
60.
Duchek JM, Hunt L., Ball K., Buckles, V., Morris JCAttention and driving performance in Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci. 1998;53:130-141.
Rizzo M., Reinach S., McGehee D., Dawson J.Simulated car crashes and crash predictors in drivers with Alzheimer disease . Arch Neurol.1997;54:545-551.
63.
Cox DJ, Quillian WC, Thorndike FP, Kovatchev BP, Hanna G.Evaluating driving performance of outpatients with Alzheimer disease . J Am Board Fam Pract.1998;11:264-271.
64.
Drachman DA, Swearer JMDriving and Alzheimer's disease: the risk of crashes. Neurology . 1993;43:2448-2456.
65.
Fox GK, Bowden SC, Bashford GM, Smith DSAlzheimer's disease and driving: prediction and assessment of driving performance . J Am Geriatr Soc.1997;45: 949-953.
66.
Mendez MFDementia and guns. J Am Geriatr Soc.1996;44:409-410.
67.
Spangenberg KB, Wagner MT, Hendrix S., Bachman DLFirearm presence in households of patients with Alzheimer's disease and related dementias. J Am Geriatr Soc.1999;47:1183-1186.
68.
Mittelman MS , Roth DL, Coon DW, Haley WESustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease . Am J Psychiatry.2004;161:850-856.
69.
Smith GE, Kokmen E., O'Brien PCRisk factors for nursing home placement in a population-based dementia cohort . J Am Geriatr Soc.2000;48:519-525.
70.
Gaugler JE, Edwards AB, Femia EE, et al. Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement. J Gerontol B Psychol Sci Soc Sci.2000;55:247-255.
71.
Knopman D., Schneider L., Davis K., et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology. 1996;47:166-177.
72.
Geldmacher DS, Provenzano G., McRae T., Mastey V., Ieni JRDonepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc.2003;51:937-944.
73.
Schulz R., O'Brien AT, Bookwala J., Fleissner K.Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist.1995 ;35: 771-791.
